This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
Subscribe To Our Newsletter & Stay Updated
